Skip to Content
Merck
All Photos(1)

Documents

V900688

Supelco

Isoniazid

Vetec™, reagent grade, 98%

Synonym(s):

4-Pyridinecarboxylic acid hydrazide, INH, Isonicotinic acid hydrazide, Isonicotinic hydrazide

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C6H7N3O
CAS Number:
54-85-3
Molecular Weight:
137.14
Beilstein:
119374
EC Number:
200-214-6
MDL number:
MFCD00006426
UNSPSC Code:
41116107
PubChem Substance ID:
329830060

grade

reagent grade

product line

Vetec™

Assay

98%

mp

171-173 °C (lit.)

format

neat

SMILES string

NNC(=O)c1ccncc1

InChI

1S/C6H7N3O/c7-9-6(10)5-1-3-8-4-2-5/h1-4H,7H2,(H,9,10)

InChI key

QRXWMOHMRWLFEY-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Antibiotic for treatment of Mycobacterium tuberculosis, inhibits mycolic acid biosynthesis. Metabolized by hepatic N-acetyltransferase (NAT) and cytochrome P450 2E1 (CYP2E1) to form hepatotoxins. Selectively induces expression of CYP2E1. Reversibly inhibits CYP2C19 and CYP3A4 activities, and mechanistically inactivates CYP1A2, CYP2A6, CYP2C19 and CYP3A4 at clinically relevant concentrations.

Legal Information

Vetec is a trademark of Merck KGaA, Darmstadt, Germany

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302,H315

Hazard Classifications

Acute Tox. 4 Oral - Skin Irrit. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Elizabeth V Arkema et al.
Annals of the rheumatic diseases, 74(6), 1212-1217 (2014-03-13)
To estimate the risk of tuberculosis (TB) in patients with rheumatoid arthritis (RA) both with and without exposure to biological therapy and to directly compare the risks between therapies. Data from the Swedish National Population Registers, Tuberculosis Register and the
Samantha Ellis et al.
Molecular pharmacology, 85(2), 269-278 (2013-11-19)
The rise in drug-resistant strains of Mycobacterium tuberculosis is a major threat to human health and highlights the need for new therapeutic strategies. In this study, we have assessed whether high-affinity iron chelators of the pyridoxal isonicotinoyl hydrazone (PIH) class
Molebogeng X Rangaka et al.
Lancet (London, England), 384(9944), 682-690 (2014-05-20)
Antiretroviral therapy reduces the risk of tuberculosis, but tuberculosis is more common in people with HIV than in people without HIV. We aimed to assess the effect of isoniazid preventive therapy on the risk of tuberculosis in people infected with
Laura Muñoz et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 60(3), 349-356 (2014-10-15)
The extent to which anti-tumor necrosis factor (TNF)-associated tuberculosis can be prevented is unclear, and there is no established guidance on the optimal screening strategy for latent tuberculosis (LTBI) in patients about to start anti-TNF therapy. We aimed to determine
Anandi Martin et al.
The Journal of antimicrobial chemotherapy, 62(1), 56-64 (2008-04-15)
The reference standard methods for drug susceptibility testing (DST) of M. tuberculosis are very slow to give results, and due to the emergence of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis, there is an urgent demand for new, rapid and
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service